Summary of the published placebo-controlled trials of bisphosphonates in patients with multiple myeloma (MM).
| . | Belch35 (1991) . | Lahtinen36 (1992) . | Berenson37 (1996) . | McCloskey38 (1998) . | Menssen39 (2002) . |
|---|---|---|---|---|---|
| Etidronate: 5 mg/kg/d per os, 24 months per os | |||||
| Clodronate: 2.4 mg/kg/d per os, 24 months (Lahtinen) and 1.6 d/day per os | |||||
| Pamidronate: 90 mg IV, monthly 24 months | |||||
| Ibandronate: 2 mg IV, monthly 12–24 months | |||||
| & Patients with no skeletal fracture at presentation | |||||
| # Patients with inhibition of bone resorption | |||||
| Abbreviations: 0, no effect; +, beneficial effect; −, harmful effect; NA, not assessed. | |||||
| No. evaluable patients | 166 | 336 | 377 | 535 | 214 |
| Bisphosphonates | Etidronate | Clodronate | Pamidronate | Clodronate | Ibandronate |
| Lytic bone lesions | 0 | + | 0 | NA | 0 |
| Pathologic fractures | 0 | 0 | + | + | 0 |
| Bone pain | 0 | 0 | + | + | 0 |
| Bone healing | 0 | NA | 0 | NA | Increase BMD |
| Hypercalcemia | 0 | 0 | + | + (trend) | 0 |
| Survival | – | 0 | + (trend) | + (subset)& | + (subset)# |
| . | Belch35 (1991) . | Lahtinen36 (1992) . | Berenson37 (1996) . | McCloskey38 (1998) . | Menssen39 (2002) . |
|---|---|---|---|---|---|
| Etidronate: 5 mg/kg/d per os, 24 months per os | |||||
| Clodronate: 2.4 mg/kg/d per os, 24 months (Lahtinen) and 1.6 d/day per os | |||||
| Pamidronate: 90 mg IV, monthly 24 months | |||||
| Ibandronate: 2 mg IV, monthly 12–24 months | |||||
| & Patients with no skeletal fracture at presentation | |||||
| # Patients with inhibition of bone resorption | |||||
| Abbreviations: 0, no effect; +, beneficial effect; −, harmful effect; NA, not assessed. | |||||
| No. evaluable patients | 166 | 336 | 377 | 535 | 214 |
| Bisphosphonates | Etidronate | Clodronate | Pamidronate | Clodronate | Ibandronate |
| Lytic bone lesions | 0 | + | 0 | NA | 0 |
| Pathologic fractures | 0 | 0 | + | + | 0 |
| Bone pain | 0 | 0 | + | + | 0 |
| Bone healing | 0 | NA | 0 | NA | Increase BMD |
| Hypercalcemia | 0 | 0 | + | + (trend) | 0 |
| Survival | – | 0 | + (trend) | + (subset)& | + (subset)# |